BCYC — Bicycle Therapeutics Share News
0.000.00%
Last trade - 00:00- $267.37m
- -$241.92m
- $72.59m
Brief: Bicycle Therapeutics, Some Units Enter Into Second Amendment To Co's Loan And Security Agreement With Hercules Capital
Brief: Bicycle Therapeutics Reports Publication Of BT7480 Preclinical Data In The Journal Of Medicinal Chemistry
Brief: Bicycle Therapeutics To Present Trials In Progress Poster Featuring Bt7480 Phase I/Ii Clinical Trial At The 2022 Asco Annual Meeting
Bicycle Therapeutics PLC reports results for the quarter ended in March - Earnings Summary
Bicycle Therapeutics PLC expected to post a loss of 68 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Curis, Sonos, Accolade, Shopify, Hoth Therapeutics
U.S. STOCKS ON THE MOVE-Curis Inc, Nvidia Corp, Veru Inc
Bicycle Therapeutics slumps after cancer therapy data update
Brief: Bicycle Therapeutics Reports FY Net Loss Of $66.8 Million
Bicycle Therapeutics PLC reports results for the quarter ended in September - Earnings Summary
Brief: Bicycle Therapeutics PLC Says QTRLY Loss Per Share $0.59
Brief: Bicycle Therapeutics Announces First Patient Dosed In Phase I/II Trial Of Bicycle Tumor-Targeted Immune Cell Agonist Bt7480
Brief: Bicycle Therapeutics Announces Publication Of Article Highlighting Preclinical Data From BT7480 Program
Bicycle Therapeutics PLC expected to post a loss of 61 cents a share - Earnings Preview
Brief: Bicycle Therapeutics PLC Announces Expansion Of Genentech Immuno-Oncology Collaboration
Bicycle Therapeutics slides on $125 mln share offering
Brief: Bicycle Therapeutics PLC Files For Offering Of Up To $125 Million Of Adss Representing Ordinary Shares
U.S. RESEARCH ROUNDUP-Hormel Foods, Omeros, Sirius XM Holdings
Brief: Bicycle Therapeutics Announces Interim BT5528 Phase I Trial Results, Prelim Results From BT8009 Phase I Clinical Trial